(Q34481810)

2 August 2017

1 reference

title

Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders (English)

1 reference

2 August 2017

1 reference

Kaiser B

1

1 reference

2 August 2017

Hoppensteadt DA

series ordinal

2

1 reference

2 August 2017

Fareed J

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

published in

1 reference

2 August 2017

volume

10

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1925-1935

1 reference

Regulation of coagulation by a multivalent Kunitz-type inhibitor

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Low molecular weight heparin in unstable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Reactivation of unstable angina after the discontinuation of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Antithrombin III in animal models of sepsis and organ failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.11.1925

10.1517/13543784.10.11.1925

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference